Key catalysts approach for Orphazyme, Gemini and Immutep.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.